Zusammenfassung
Affektionen des visuellen Systems treten im Rahmen vieler neurologischer Erkrankungen auf. Insbesondere demyelinisierende Prozesse des Zentralnervensystems (ZNS) wie die Multiple Sklerose (MS) können mit einer Vielzahl ophthalmologischer Störungen einhergehen. Während die Optikusneuritis (ON) als Symptom dieser Erkrankung gewertet werden kann, scheint es sich bei dem gehäuften Auftreten von Uveitiden bei MS-Patienten eher um die Koinzidenz zweier unabhängiger Erkrankungen im Rahmen einer gemeinsamen Autoimmundiathese zu handeln. Aufgrund des hohen Konversionsrisikos in eine klinisch sichere MS besteht daher bei der isolierten ON bei entsprechender Läsionslast in der magnetresonanztomographischen Darstellung des Neurokraniums die Indikation zur Einleitung einer Frühtherapie mit Interferon-β, während die derzeitige Datenlage bei der Uveitis einen frühzeitigen Einsatz immunmodulatorischer Medikamente nicht rechtfertigt. Da die MS-assoziierte Uveitis dem Auftreten neurologischer Symptome jedoch ebenfalls um Jahre vorausgehen kann und ein Ansprechen auf schubtherapeutische und -prophylaktische Medikamente ähnliche pathogenetische Mechanismen nahe legt, bleibt in weiteren Studien zu prüfen, inwiefern durch magnetresonanztomographische oder immunologische Prädiktoren diejenigen Uveitispatienten identifiziert werden können, bei denen der Einsatz einer immunmodulatorischen Frühtherapie die Entwicklung einer klinisch manifesten MS verzögern oder verhindern kann.
Summary
An involvement of the visual system can be found in many neurologic diseases. Especially demyelinating processes of the central nervous system (CNS) and multiple sclerosis (MS) in particular present with a variety of ophthalmological abnormalities. While optic neuritis (ON) is known to be a positive predictor for the development of MS and can be considered a symptom of the disease, the high frequency of uveitis observed in MS patients seems to occur rather in the context of a general predisposition for autoimmune disorders. However, MS-associated uveitis can precede the onset of neurological symptoms by many years and shows response to treatment with steroids and interferons, suggesting the presence of similar underlying pathogenic mechanisms. Therefore, further studies are warranted in order to reveal whether administration of early immunomodulatory therapy can delay or even prevent the clinical manifestation of MS in a distinct subgroup of patients presenting with uveitis.
Literatur
Schmidt RM, Hoffmann FA (Hrsg) (2006) Multiple Sklerose. Urban & Fischer, München
Kidd D, Burton B, Plant GT, Graham EM (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126: 276–284
Horvath R, Abicht A, Shoubridge EA et al. (2000) Leber’s hereditary optic neuropathy presenting as multiple sclerosis-like disease of the CNS. J Neurol 247: 65–67
Bloch-Michel E, Nussenblatt RB (1987) International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103: 234–235
Pras E, Neumann R, Zandman-Goddard G et al. (2004) Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum 34: 602–609
Maca SM, Scharitzer M, Barisani-Asenbauer T (2006) Uveitis and neurologic diseases: an often overlooked relationship. Wien Klin Wochenschr 118/9–10: 273–279
Smith JR, Rosenbaum JT (2004) Neurological concomitants of uveitis. Br J Ophthalmol 88: 1498–1499
Rucker CW (1944) Sheathing of the retinal veins in multiple sclerosis. Mayo Clin Proc 19: 176–178
Newman NJ (1998) Multiple Sclerosis. In: Miller NR, Newman NJ (eds) Walsh and Hoyt‚s clinical neuroophthalmology. 5th edn. Williams & Wilkins, Baltimore, pp 5539–5676
Biousse V, Trichet C, Bloch-Michel E, Roullet E (1999) Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52: 179–181
Malinowski SM, Pulido JS, Folk JC (1993) Long term visual outcome and complications assiociated with pars planitis. Ophthalmology 100: 818–825
Wakefield D, Jennings SA, McCluskey PJ (2000) Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis. Clin Exp Ophthalmol 28: 103–106
Becker MD, Heiligenhaus A, Hudde T et al. (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89: 1254–1257
Mikuls TR, Moreland LW (2003) Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 26: 23–32
The Lenercept Study Group, The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: Results of a randomized, placebo-controlled muticenter study. Neurology 53: 457–465
Oosten BW van, Barkhof F, Truyen L et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531–1534
Adamus G, Burrows GG, Vandenbark AA, Offner H (2006) Treatment of autoimmune anterior uveitis with recombinant TCR ligands. Invest Ophthalmol Vis Sci 47: 2555–2561
Söderström M, Ya-Ping J, Hillert J, Link H (1998) Optic neuritis: prognosis for multiple sclerosis from MRI, CSF and HLA-findings. Neurology 50: 708–714
Söderström M (2001) Optic neuritis and multiple sclerosis. Acta Ophthalmol Scand 79: 223–227
Rizzo JF 3rd, Lessell S (1988) Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long term prospective study. Neurology 38: 185–190
Optic Neuritis Study Group (2003) High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis – experience of the optic neuritis treatment trial. Arch Ophthalmol 121: 944–949
Rodriguez M, Siva A, Cross SA et al. (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45: 244–250
Sandberg-Wollheim M, Bynke H, Cronqvist S et al. (1990) A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 27: 386–393
Jacobs LD, Beck RW, Simon JH et al. (2000) Intramuscular Interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343: 898–904
CHAMPS Study Group (2001) Interferon β-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 132: 463–471
O‘Riordan JI, Thompson AJ, Kingsley DP (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 121: 495–503
Optic Neuritis Study Group (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49: 1404–1413
Brex PA, Ciccarelli O, O‘Riordan JI et al. (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346: 158–164
Söderström M, Lindqvist M, Hillert J et al. (1994) Optic neuritis: findings on MRI, CSF, examination and HLA class II typing in 60 patients and results of a short-term follow-up. J Neurol 241: 391–397
Ghezzi A, Martinelli V, Torri V (1999) Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome and the prognostic role of paraclinical tests. J Neurol 246: 770–775
Tintore M, Rovira A, Rio J et al. (2006) Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67: 968–972
Arnold AC (2005) Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 139: 1101–1108
Beck RW, Cleary PA, Anderson MM et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326: 581–588
Optic Neuritis Study Group (2004) Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137: 77–83
Edwards LJ, Constantinescu CS (2004) A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler 10: 575–581
Raja SC, Jabs DA, Dunn JP et al. (1999) Clinical features and class II HLA associations. Ophthalmology 106: 594–599
Adamus G, Amundson D, Vainiene M et al. (1996) Myelin basic protein specific T-helper cells induce experimental anterior uveitis. J Neurosci Res 44: 513–518
Gorczyca WA, Ejma M, Witkowska D et al. (2004) Retinal antigens are recognized by antibodies present in sera of patients with multiple sclerosis. Ophthalmic Res 36: 120–123
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beyer, AM., Rosche, B., Pleyer, U. et al. Stellenwert der Uveitis im Rahmen demyelinisierender Erkrankungen des Zentralnervensystems. Nervenarzt 78, 1389–1398 (2007). https://doi.org/10.1007/s00115-007-2297-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-007-2297-x